학술논문
Genetically adjusted PSA levels for prostate cancer screening.
Document Type
article
Author
Kachuri, Linda; Hoffmann, Thomas J; Jiang, Yu; Berndt, Sonja I; Shelley, John P; Schaffer, Kerry R; Machiela, Mitchell J; Freedman, Neal D; Huang, Wen-Yi; Li, Shengchao A; Easterlin, Ryder; Goodman, Phyllis J; Till, Cathee; Thompson, Ian; Lilja, Hans; Van Den Eeden, Stephen K; Chanock, Stephen J; Haiman, Christopher A; Conti, David V; Klein, Robert J; Mosley, Jonathan D; Graff, Rebecca E; Witte, John S
Source
Nature medicine. 29(6)
Subject
Language
Abstract
Prostate-specific antigen (PSA) screening for prostate cancer remains controversial because it increases overdiagnosis and overtreatment of clinically insignificant tumors. Accounting for genetic determinants of constitutive, non-cancer-related PSA variation has potential to improve screening utility. In this study, we discovered 128 genome-wide significant associations (P